Clinical Trials Browser

Interventional × Neoplasms, Plasma Cell × carfilzomib × Clear all

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04822337 2026-01-20

Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03500445 2025-10-03

Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03314636 2025-08-08

CONPET

Phase 2 Active not recruiting

Neoplasms, Plasma Cell

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03773107 2025-01-13

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

Phase 1/2 Completed

12 enrolled 19 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Phase 1/2 Terminated

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT03289299 2023-12-12

ASCENT

Phase 2 Active not recruiting

Smoldering Multiple Myeloma, Neoplasms, Plasma Cell

NCT04065789 2022-01-27

KyDaR

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01554852 2018-06-11

Myeloma XI

Phase 3 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase 1 Completed

48 enrolled 26 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Phase 2 Completed

50 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT01279694 2016-04-13

CARMYSAP

Phase 1/2 Completed

Neoplasms, Plasma Cell

NCT02114502 2014-07-11

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Phase 2 Withdrawn

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell